JP2007513896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513896A5 JP2007513896A5 JP2006543369A JP2006543369A JP2007513896A5 JP 2007513896 A5 JP2007513896 A5 JP 2007513896A5 JP 2006543369 A JP2006543369 A JP 2006543369A JP 2006543369 A JP2006543369 A JP 2006543369A JP 2007513896 A5 JP2007513896 A5 JP 2007513896A5
- Authority
- JP
- Japan
- Prior art keywords
- ucl
- receptor
- pharmaceutical formulation
- fub
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 229940125425 inverse agonist Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000004031 partial agonist Substances 0.000 claims 7
- 239000002464 receptor antagonist Substances 0.000 claims 5
- 229940044551 receptor antagonist Drugs 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 239000002469 receptor inverse agonist Substances 0.000 claims 4
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 4
- WNWALBVQAAIULR-UHFFFAOYSA-N 5-(3-phenylmethoxypropyl)-1H-imidazole Chemical compound C=1N=CNC=1CCCOCC1=CC=CC=C1 WNWALBVQAAIULR-UHFFFAOYSA-N 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 3
- 206010013654 Drug abuse Diseases 0.000 claims 3
- -1 Immoproxyfan Chemical compound 0.000 claims 3
- 208000030990 Impulse-control disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 208000019899 phobic disease Diseases 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 2
- QIQWRCNAPQJQLL-COALEZEGSA-N (z)-but-2-enedioic acid;5-[(1r,2r)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1h-imidazole Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)CCC#C[C@@H]1C[C@H]1C1=CN=CN1 QIQWRCNAPQJQLL-COALEZEGSA-N 0.000 claims 2
- CXNCQFJNXQAFND-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[[4-(1h-imidazol-5-ylmethyl)phenyl]methyl]urea Chemical compound ClC1=CC(Cl)=CC(NC(=O)NCC=2C=CC(CC=3N=CNC=3)=CC=2)=C1 CXNCQFJNXQAFND-UHFFFAOYSA-N 0.000 claims 2
- ZRIVDXCYPBUSKL-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-1-(7-pyrrolidin-1-ylheptyl)guanidine Chemical compound C=1C=C(Cl)C=CC=1CN(C(=N)N)CCCCCCCN1CCCC1 ZRIVDXCYPBUSKL-UHFFFAOYSA-N 0.000 claims 2
- CPOUJACQGWJJQB-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[2-(1h-imidazol-5-yl)ethyl]-1,2,4-oxadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NOC(CCC=2N=CNC=2)=N1 CPOUJACQGWJJQB-UHFFFAOYSA-N 0.000 claims 2
- RHMNKKOAWUCDRK-UHFFFAOYSA-N 4-(3-piperidin-1-ylpropoxy)benzonitrile Chemical compound C1=CC(C#N)=CC=C1OCCCN1CCCCC1 RHMNKKOAWUCDRK-UHFFFAOYSA-N 0.000 claims 2
- DCQNAFOCXVCDLB-UHFFFAOYSA-N 5-[3-[(4-iodophenyl)methoxy]propyl]-1h-imidazole Chemical compound C1=CC(I)=CC=C1COCCCC1=CN=CN1 DCQNAFOCXVCDLB-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 2
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical group C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229960001653 citalopram Drugs 0.000 claims 2
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 claims 2
- 229960004606 clomipramine Drugs 0.000 claims 2
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims 2
- 229960005217 dapoxetine Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002866 duloxetine Drugs 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 229960004341 escitalopram Drugs 0.000 claims 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 2
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims 2
- 229950003930 femoxetine Drugs 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- WROHEWWOCPRMIA-UHFFFAOYSA-N gsk-189,254 Chemical compound N1=CC(C(=O)NC)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 WROHEWWOCPRMIA-UHFFFAOYSA-N 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- MZCJWLAXZRFUPI-UHFFFAOYSA-N impentamine Chemical compound NCCCCCC1=CN=CN1 MZCJWLAXZRFUPI-UHFFFAOYSA-N 0.000 claims 2
- PTKHFRNHJULJKT-UHFFFAOYSA-N jnj-5207852 Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PTKHFRNHJULJKT-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 2
- 229960001800 nefazodone Drugs 0.000 claims 2
- BWRRXOIACQYNEK-UHFFFAOYSA-N o-[2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate Chemical compound C1=CC(Cl)=CC=C1NC(=S)OCCN1C(=O)C2=CC=CC=C2C1=O BWRRXOIACQYNEK-UHFFFAOYSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- LIWQRVPGHLYPQJ-JEJOPICUSA-N (e)-1-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C(=O)N1[C@H](CN2CCCC2)CCC1 LIWQRVPGHLYPQJ-JEJOPICUSA-N 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- UBHYDQAARZKHEZ-UHFFFAOYSA-N N'-[2-(4-iodophenyl)ethyl]carbamimidothioic acid 3-(1H-imidazol-5-yl)propyl ester Chemical compound C=1C=C(I)C=CC=1CCN=C(N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960003740 vilazodone Drugs 0.000 claims 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52949103P | 2003-12-15 | 2003-12-15 | |
| US60/529,491 | 2003-12-15 | ||
| DKPA200301854 | 2003-12-15 | ||
| DKPA200301854 | 2003-12-15 | ||
| PCT/DK2004/000862 WO2005056056A2 (en) | 2003-12-15 | 2004-12-14 | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513896A JP2007513896A (ja) | 2007-05-31 |
| JP2007513896A6 JP2007513896A6 (ja) | 2007-09-06 |
| JP2007513896A5 true JP2007513896A5 (enExample) | 2008-01-17 |
Family
ID=34680191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006543369A Withdrawn JP2007513896A (ja) | 2003-12-15 | 2004-12-14 | セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1696896A2 (enExample) |
| JP (1) | JP2007513896A (enExample) |
| AU (1) | AU2004296531A1 (enExample) |
| BR (1) | BRPI0415899A (enExample) |
| NO (1) | NO20063267L (enExample) |
| WO (1) | WO2005056056A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004283196B2 (en) | 2003-09-17 | 2011-08-25 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| US8026240B2 (en) | 2007-09-11 | 2011-09-27 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CN114652671A (zh) * | 2020-12-23 | 2022-06-24 | 上海博志研新药物技术有限公司 | 维拉佐酮药物组合物、其制备方法及应用 |
| KR20250154480A (ko) * | 2023-02-28 | 2025-10-28 | 바이오하벤 테라퓨틱스 리미티드 | 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9692898A (en) * | 1997-10-17 | 1999-05-10 | Eli Lilly And Company | Potentiation of pharmaceuticals |
| JP2002516282A (ja) * | 1998-05-22 | 2002-06-04 | イーライ・リリー・アンド・カンパニー | 難治性鬱病の処置のための組合せ治療 |
| TR200003525T2 (tr) * | 1998-05-29 | 2001-04-20 | Eli Lilly And Company | Bipolar bozuklukların tedavisi için kombinasyon terapisi |
| EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
-
2004
- 2004-12-14 WO PCT/DK2004/000862 patent/WO2005056056A2/en not_active Ceased
- 2004-12-14 BR BRPI0415899-7A patent/BRPI0415899A/pt not_active IP Right Cessation
- 2004-12-14 JP JP2006543369A patent/JP2007513896A/ja not_active Withdrawn
- 2004-12-14 AU AU2004296531A patent/AU2004296531A1/en not_active Abandoned
- 2004-12-14 EP EP04803015A patent/EP1696896A2/en not_active Withdrawn
-
2006
- 2006-07-13 NO NO20063267A patent/NO20063267L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513052A5 (enExample) | ||
| JP2009538331A5 (enExample) | ||
| JP2009538331A (ja) | 抑うつ障害のための治療 | |
| JP2023100904A5 (enExample) | ||
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| US6172105B1 (en) | Composition and methods employing it for the treatment of 5-HT-mediated disorders | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| US20130217776A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Agomelatine | |
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| NO20081733L (no) | Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling | |
| JP2007513896A5 (enExample) | ||
| CL2009000980A1 (es) | Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006). | |
| Nutt | Beyond psychoanaleptics–can we improve antidepressant drug nomenclature? | |
| HRP20120713T1 (hr) | Kombinacija analeptičkog modafinila i antidepresiva za liječenje depresije | |
| CA2490638A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
| JP2006514952A5 (enExample) | ||
| JP2007505156A5 (enExample) | ||
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| GEP20074225B (en) | Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| WO2004100940B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| JP2007502785A5 (enExample) | ||
| WO2005056056A3 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| AR045314A1 (es) | Composiciones farmaceuticas de analepticos y antidepresivos | |
| AR048134A1 (es) | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial | |
| CA2537747A1 (en) | The combination of a serotonin reuptake inhibitor and loxapine |